- Erscheinungsweise vierteljährlich
- ca. 70 Seiten
- ISSN 2511-7157
- Sprache: Englisch
AN EPLR SERIES: COVID-19 and European Pharmaceutical Law
In the wake of the COVID-19 pandemic, the European Pharmaceutical Law Review (EPLR) has establish a series for expert insights into the EU and Member State responses to this public health crisis, focussing on pharmaceutical and medical device law and policy:
* All contributions will be published in a later edition of the European Pharmaceutical Law Review (EPLR).
Issue 1/2020 – The Pharma Sector in the Age of AI
Reflecting the growing impact of Artificial Intelligence on the pharmaceutical sector, Issue 1/2020 of EPLR features articles on AI as a medical device, the patentability of AI generated drugs and the EU – US Privacy Shield Regime.
In addition to the articles this issue features reports on medicine shortages and the effectiveness of therapeutic and biosimilar pharmaceutical competition. Concluding the issue we have a Case Note on Case T-733/17 GMPO which addressed problems with the orphan designation procedure.
View the whole table of content of EPLR 1/2020: Here
The European Pharmaceutical Law Review (EPLR) is seeking original research papers for a special issue on global pharmaceutical law and policy.
Please see for details our Special Call for Papers